Skip to content
Loop Biz – Lifestyle
Author:
Apollo Therapeutics
Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations
August 25, 2026
Apollo Therapeutics Appoints Timothy P. Walbert as Chairman of the Board
June 9, 2026